

Monday, 12 October 2020

Dear Shareholder

**ZELIRA THERAPEUTICS LIMITED – UPCOMING ANNUAL GENERAL MEETING OF SHAREHOLDERS**

Zelira Therapeutics Limited (ASX:ZLD) (Zelira or the Company) will hold its Annual General Meeting of its shareholders (Shareholders) at 9.00am (WST) on Friday, 13 November 2020 (the AGM or Meeting). The Company advises shareholders that the AGM will be held in compliance with the Australian government's restrictions on public gatherings.

In accordance with temporary modifications to the Corporations Act under the Corporations (Coronavirus Economic Response) Determination (No. 3) 2020, the Company is not sending hard copies of the Notice of Meeting to Shareholders. The Notice of Meeting can be viewed and downloaded from this website link <https://zeliratx.com/asx-2020/>

Due to the COVID-19 situation, it may not be possible for Shareholders to physically attend the Meeting. As a result, the Company strongly encourages all Shareholders to vote by directed proxy in lieu of attending the meeting in person. Proxy forms for the meeting should be lodged before 9.00am (WST) on Wednesday, 11 November 2020. A copy of your personalised Proxy form is enclosed for convenience.

As at the date of this Notice, the Company intends to hold a physical in-person AGM, so long as the number of attendees remains within the limits permitted under the latest public gathering restriction guidelines. In the event that the number of attendees exceeds that permitted, the Meeting Chairperson will adjourn the Meeting in the interests of the safety of all involved, for it to be resumed at a later date.

If it becomes necessary to make changes to the current arrangements for the AGM, Zelira Therapeutics will advise Shareholders through its website and by making an ASX announcement.

If the above arrangements with respect to the Meeting change, shareholders will be updated via the ASX Market Announcements Platform and also via the Company's website at <https://zeliratx.com/asx-2020/>.

The Notice and the accompanying Explanatory Memorandum should be read in its entirety. If a shareholder is in doubt as to how to vote, that shareholder should seek advice from an accountant, solicitor or other professional adviser prior to voting.

The Company appreciates the understanding of shareholders during this time.

Yours faithfully

**Osagie Imasogie**  
**Chairman**  
**Zelira Therapeutics Limited**

This announcement was approved and authorised for release by the Board of Zelira Therapeutics Limited.

